Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated warning text exactly matches the FDA labeling language in Section 5.1 regarding increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs.
Category Scores
Accurate Statements
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Label Section 5.1: “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
Unsupported Statements
Contradictions
Important Omissions
The claim did not include the label’s additional boxed-warning context that INVEGA (paliperidone) is not approved for the treatment of dementia-related psychosis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided warning statement is directly supported by the label and does not introduce incorrect or contradictory information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s explicit note that INVEGA is not approved for dementia-related psychosis.
Suggested Improvement
Include the label’s additional statement from Section 5.1: “INVEGA (paliperidone) is not approved for the treatment of dementia-related psychosis.”